Created to combat obesity and diabetes, GLP-1 agonists are now being assessed in dozens of disorders
The American Diabetes Association now recommends GLP-1 RAs for patients with established ASCVD regardless of their A1C and regardless of if the patient is taking metformin, the historically first line medication for T2DM [38]
Our study detected a robust genetic association with GLP1 medication weight loss efficacy and associated side effects
GLP-1 medications like Ozempic, Mounjaro, and Wegovy are commonly prescribed to help manage type 2 diabetes and support weight loss
After stopping, it takes roughly 5 half-lives (about 30 days) for the compound to clear the body
Clinical trials from the PIONEER program demonstrated significant glycemic reductions with oral semaglutide, although higher doses are often required to approach the potency of injectable formulations